Research Institute of the McGill University Health Centre
Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Active, not recruiting | Phase 3 | 2026-10-01 | NCT04562389 | |
| Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety | Cow's Milk Allergy, Egg Hypersensitivity, Hypersensitivity, Immediate, Milk Hypersensitivity, Nut and Peanut Hypersensitivity, Peanut Hypersensitivity, food allergy, immune system disorder | Recruiting | Not applicable | 2026-05-07 | NCT06256146 | |
| Social Prescribing to Improve Adherence and Outcomes in Women With Heart Failure | Heart Decompensation, Myocardial Failure, cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2026-02-20 | NCT06628973 | |
| A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood platelet disease, bone marrow disorder, hematologic disorder, primary myelofibrosis, thrombocytopenia | Recruiting | Phase 2 | 2026-02-12 | NCT05980806 | |
| A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | Insulin Resistance, Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperinsulinism, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Phase 3 | 2025-03-30 | NCT06894784 | |
| Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide | Insulin Resistance, Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperinsulinism, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Phase 2 / Phase 3 | 2024-12-18 | NCT06387199 |